Phimedix PLC Strategy Update (2477M)
May 07 2020 - 2:00AM
UK Regulatory
TIDMPHM
RNS Number : 2477M
Phimedix PLC
07 May 2020
Phimedix Plc
("Phimedix" or "the Company")
Strategy Update
7 May 2020
Following completion of the proposals outlined in the circular
to shareholders dated 14 February 2020, the Board of Phimedix
provides the following update.
On 11 March 2020, Phimedix became an AIM Rule 15 cash shell and
as such is required to make an acquisition or acquisitions which
constitute(s) a reverse takeover under AIM Rule 14 within six
months, failing which, the Company's Ordinary Shares would then be
suspended from trading on AIM pursuant to AIM Rule 40. Admission to
trading on AIM would be cancelled six months from the date of
suspension should the reason for the suspension not have been
rectified.
At the time of the general meeting in March, no specific
acquisition strategy had been defined. Recent global events have
caused a slight delay in the search for an acquisition target for
the Company, but with future visibility returning, the Board is now
in a position to consider a suitable strategy for the Company.
The Board is of the view that, even in the current environment,
there are potential acquisition opportunities in the technology and
life sciences sectors in particular and has decided to focus its
efforts initially in these two areas. However, as yet, no
discussions have started between the Company and any potential
targets.
The Annual Report and Accounts, for the year ended 31 March
2020, are in the process of being prepared. The Company anticipates
that it will release its final results around the end of July
2020.
Further announcements will be made as appropriate.
For further information please contact:
Phimedix Plc Please email any enquiries
Nicholas Nelson, Director to nelson@nexfin.org.uk
Ajay Rajpal, Director
SPARK Advisory Partners Limited (Nominated
Adviser)
Mark Brady or Neil Baldwin
www.sparkadvisorypartners.com +44 (0) 203 368 3551
SI Capital Ltd (Broker)
Nick Emerson
www.sicapital.co.uk +44 (0)1483 413500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDKZGGKKNNGGZG
(END) Dow Jones Newswires
May 07, 2020 02:00 ET (06:00 GMT)
Phimedix (LSE:PHM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Phimedix (LSE:PHM)
Historical Stock Chart
From Nov 2023 to Nov 2024